


**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions and listings of claims in the application:

**LISTING OF CLAIMS:**

1. (currently amended): A compound represented by formula (I)



wherein R<sup>1</sup> and R<sup>2</sup> each independently represents a hydrogen atom, C1-8 alkyl, a halogen atom, C1-4 alkoxy, nitro, trihalomethyl, trihalomethoxy, trihalomethylthio, cyano, C1-4 alkylthio or NR<sup>7</sup>R<sup>8</sup>, in which R<sup>7</sup> and R<sup>8</sup> each independently represents a hydrogen atom or C1-4 alkyl;

R<sup>3</sup> represents C1-8 alkyl which may be substituted with a 1-3 halogen atom(s) or phenyl;

R<sup>4</sup> represents a hydrogen atom or C1-8 alkyl;

R<sup>5</sup> and R<sup>6</sup> each independently represents a hydrogen atom or C1-4 alkyl, or R<sup>5</sup> and R<sup>6</sup> may be together with their neighboring carbon atom to form a carbocyclic ring;

X represents a sulfur atom, an oxygen atom or a nitrogen atom which may have a substituent(s);

ringA represents a cyclic group which may have a substituent(s),

4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 3,4-dihydro-1H-isoquinolin-2-yl,

or a salt thereof, or a solvate thereof or a prodrug thereof.

**2. (currently amended):** The compound according to claim 1, wherein the cyclo group represented by ring A is 4-(trifluoromethyl)phenyl, 4-(trifluoromethoxy)phenyl, 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl, 4-phenylpiperidin-1-yl, 4-phenylpiperazin-1-yl, 1,3-dihydro-2H-isoindole-2-yl, 4-(4-chlorophenyl)piperazin-1-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

**3. (currently amended):** The compound according to claim 21, wherein the cyclo group represented by ring A is 4-(trifluoromethyl)piperidin-1-yl, 2,2-difluoro-1,3-benzodioxol-5-yl or 3,4-dihydro-1H-isoquinolin-2-yl.

**4. (currently amended):** The compound according to claim 1, wherein the compound is

- (1) [3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid,
- (2) [3-(2-{5-isopropyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid;
- (3)(2) [3-(2-{5-ethyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)-4-methylphenyl]acetic acid,
- (4) [3-(2-{5-isopropyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid;
- (5)(3) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,
- (6) [3-(2-{5-ethyl-2-[4-(trifluoromethoxy)phenyl]-1,3-oxazol-4-yl}ethoxy)-4-methylphenyl]acetic acid;

- (7)(4) (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-methyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid,
- (8)(5) [2-fluoro-3-(2-(5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl)ethoxy]phenyl]acetic acid,
- (9) (2-fluoro-3-(2-[5-methyl-2-(4-phenylpiperidin-1-yl)-1,3-thiazol-4-yl]ethoxy)phenyl)acetic acid,
- (10) (3-[2-[5-methyl-2-(4-phenylpiperazine-1-yl)-1,3-thiazol-4-yl]ethoxy]phenyl)acetic acid;
- (11) (3-[2-[2-(1,3-dihydro-2H-isoindole-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy]-2-fluorophenyl)acetic acid,
- (12) [3-(2-[4-(4-chlorophenyl)piperazine-1-yl]-5-methyl-1,3-thiazol-4-yl]ethoxy]-2-fluorophenyl]acetic acid or
- (13)(6) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid.

**5. (currently Amended):** A pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, or a salt thereof, or a solvent thereof or a prodrug thereof, and a pharmaceutically acceptable carrier.

**6. (currently amended):** The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is a preventive and/or therapeutic agent for a PPAR-mediated disease hyperlipidemia or adiposity.

7-8 (canceled).

**9. (currently amended):** A medicament pharmaceutical composition comprising the compound represented by formula (I) according to claim 1, or a salt thereof, or a solvent thereof or a prodrug thereof and one kind or more kinds components selected from the group consisting of a MTP inhibitor, a HMG-CoA reductase inhibitor, a squalene synthase inhibitor, a fibrate drug, an ACAT inhibitor, a 5-lipoxygenase inhibitor, a cholesterol absorption inhibitor, a bile acid absorption inhibitor, a Na<sup>+</sup>/bile acid transporter inhibitor, LDL receptor activator, LDL receptor expression enhancer, a pancreatic lipase inhibitor, a probucol formulation, a nicotine acid formulation and a cholesterol ester transporter protein inhibitor.

**10. (currently amended):** A method for prevention and/or treatment ~~for~~<sup>of</sup> PPAR-mediated disease hyperlipidemia or adiposity in a mammal, which comprises administering to a mammal an effective amount of a compound represented by formula (I) according to claim 1, selected from the group consisting of

- (1) (3-[2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy]-4-methylphenyl)acetic acid,
- (2) [2-fluoro-3-(2-[5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl]ethoxy)phenyl]acetic acid, and
- (3) (3-[2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy]-4-methylphenyl)acetic acid  
or a salt thereof, or a solvent thereof or a prodrug thereof.

**11. (Canceled)**

**12. (new):** A compound selected from a group consisting of

- (1) (3-{2-[2-(3,4-dihydro-1H-isoquinolin-2-yl)-5-methyl-1,3-thiazol-4-yl]ethoxy}-4-methylphenyl)acetic acid and
- (2) [2-fluoro-3-(2-{5-methyl-2-[4-(trifluoromethyl)piperidin-1-yl]-1,3-thiazol-4-yl}ethoxy)phenyl]acetic acid.

**13. (new):** A compound of (3-{2-[2-(2,2-difluoro-1,3-benzodioxol-5-yl)-5-isopropyl-1,3-oxazol-4-yl]ethoxy}-4-methylphenyl)acetic acid.